Noninvasive Biomarkers to Assess Risk of Clinical Outcomes
Longitudinal ELF, VCTE, and MRE thresholds linked to cirrhosis progression, hepatic decompensation, hepatocellular carcinoma, and survival.
Noninvasive tests do more than stage your liver on day one: tracking how they move over time tells you and your care team where your risk is headed. For instance, an ELF score at or above 9.8, a baseline FibroScan stiffness at or above 16.6 kPa, a 20% jump in FibroScan kPa, or a 15% rise in MRE stiffness all signal meaningfully higher odds of progressing toward cirrhosis or liver complications over the next 1.5 to 4 years. That also works in your favor: stabilizing or lowering those numbers is a real, measurable sign that your treatment plan is protecting your liver.
Prognostic Thresholds Associated With Progression and Liver-Related Outcomes
| Biomarker | Criteria | Outcome Assessed | Comparative Risk | Median Follow-Up |
|---|---|---|---|---|
| ELF™ | ≥9.76 | Progression to cirrhosis | 22% | 2.4 years |
| ≥9.8 | Hepatic decompensation, HCC, or PHTN | 25% vs 2.9% | 4.2 years | |
| ≥11.27 | Hepatic decompensation, MELD ≥15 or ≥2-point increase in CP score, or death | 19% | 2.4 years | |
| LSM by VCTE™ | Baseline kPa ≥16.6 | Progression to cirrhosis | 31.1% vs 9.1% | 1.4 years |
| ≥5% kPa and ≥20% increase in kPa | Progression to cirrhosis | 22.2% vs 14% | 1.4 years | |
| Baseline kPa ≥13 | Hepatic decompensation, HCC, or PHTN | 17% vs 0.5% | 4.2 years | |
| Baseline kPa ≥21 | Hepatic decompensation | 14% vs 2% | 3 years | |
| Baseline kPa ≥30.7 | Hepatic decompensation, OLT, MELD ≥15, or death | 11.1% vs 1.4% | 1.4 years | |
| Per 1 unit increase in kPa | Hepatic decompensation, HCC, or PHTN | 7% increase in hazard | N/A | |
| >20% increase in kPa | Hepatic decompensation | 14.4% vs 10% | 3 years | |
| >20% increase in kPa | HCC | 6.7% vs 5.8% | 3 years | |
| >20% increase in kPa | Liver-related death | 10.6% vs 9.8% | 3 years | |
| >20% increase in kPa | Overall death | 7.7% vs 6.5% | 3 years | |
| LSM by MRE | ≥15% increase in kPa | Fibrosis progression ≥1 stage | 47.1% vs 20% | 1.4 years |
| Baseline kPa >5 vs <3.63 | Hepatic decompensation, HCC, or death | 25% vs 0% | 3 years |